1月14日,药明合联发布2025财年盈喜公告,同时还披露其发起以现金要约方式收购东曜药业股份。从盈喜公告可见,药明合联2025年营收同比增长超45%;毛利同比增长超70%;经调整净利润(不含利息收入和支出)同比增长超45%,扣除汇率变动影响后,该增长率预期将超过65%。同时宣布以4港元/股价格,收购东曜药业股份约7.73亿股,总估值约达30.91 亿港元。该价格较东曜药业股份于未受干扰日在联交所所...
Source Link1月14日,药明合联发布2025财年盈喜公告,同时还披露其发起以现金要约方式收购东曜药业股份。从盈喜公告可见,药明合联2025年营收同比增长超45%;毛利同比增长超70%;经调整净利润(不含利息收入和支出)同比增长超45%,扣除汇率变动影响后,该增长率预期将超过65%。同时宣布以4港元/股价格,收购东曜药业股份约7.73亿股,总估值约达30.91 亿港元。该价格较东曜药业股份于未受干扰日在联交所所...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.